Literature DB >> 20861247

Structural characterization of the dual glycan binding adeno-associated virus serotype 6.

Robert Ng1, Lakshmanan Govindasamy, Brittney L Gurda, Robert McKenna, Olga G Kozyreva, R Jude Samulski, Kristin N Parent, Timothy S Baker, Mavis Agbandje-McKenna.   

Abstract

The three-dimensional structure of adeno-associated virus (AAV) serotype 6 (AAV6) was determined using cryo-electron microscopy and image reconstruction and using X-ray crystallography to 9.7- and 3.0-Å resolution, respectively. The AAV6 capsid contains a highly conserved, eight-stranded (βB to βI) β-barrel core and large loop regions between the strands which form the capsid surface, as observed in other AAV structures. The loops show conformational variation compared to other AAVs, consistent with previous reports that amino acids in these loop regions are involved in differentiating AAV receptor binding, transduction efficiency, and antigenicity properties. Toward structure-function annotation of AAV6 with respect to its unique dual glycan receptor (heparan sulfate and sialic acid) utilization for cellular recognition, and its enhanced lung epithelial transduction compared to other AAVs, the capsid structure was compared to that of AAV1, which binds sialic acid and differs from AAV6 in only 6 out of 736 amino acids. Five of these residues are located at or close to the icosahedral 3-fold axis of the capsid, thereby identifying this region as imparting important functions, such as receptor attachment and transduction phenotype. Two of the five observed amino acids are located in the capsid interior, suggesting that differential AAV infection properties are also controlled by postentry intracellular events. Density ordered inside the capsid, under the 3-fold axis in a previously reported, conserved AAV DNA binding pocket, was modeled as a nucleotide and a base, further implicating this capsid region in AAV genome recognition and/or stabilization.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861247      PMCID: PMC3004313          DOI: 10.1128/JVI.01235-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Situs: A package for docking crystal structures into low-resolution maps from electron microscopy.

Authors:  W Wriggers; R A Milligan; J A McCammon
Journal:  J Struct Biol       Date:  1999 Apr-May       Impact factor: 2.867

2.  A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini.

Authors:  Stephanie Kronenberg; Bettina Böttcher; Claus W von der Lieth; Svenja Bleker; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 3.  Adeno-associated virus vectors in clinical trials.

Authors:  Barrie J Carter
Journal:  Hum Gene Ther       Date:  2005-05       Impact factor: 5.695

4.  Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1.

Authors:  Edward B Miller; Brittney Gurda-Whitaker; Lakshmanan Govindasamy; Robert McKenna; Sergei Zolotukhin; Nicholas Muzyczka; Mavis Agbandje-McKenna
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-11-30

5.  Structure of adeno-associated virus serotype 8, a gene therapy vector.

Authors:  Hyun-Joo Nam; Michael Douglas Lane; Eric Padron; Brittney Gurda; Robert McKenna; Erik Kohlbrenner; George Aslanidi; Barry Byrne; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

6.  Version 1.2 of the Crystallography and NMR system.

Authors:  Axel T Brunger
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

7.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942).

Authors:  Michael Schmidt; Lakshmanan Govindasamy; Sandra Afione; Nick Kaludov; Mavis Agbandje-McKenna; John A Chiorini
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

10.  Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.

Authors:  Haiyan Jiang; David Lillicrap; Susannah Patarroyo-White; Tongyao Liu; Xiaobing Qian; Ciaran D Scallan; Sandra Powell; Tracey Keller; Morag McMurray; Andrea Labelle; Dea Nagy; Joseph A Vargas; Shangzhen Zhou; Linda B Couto; Glenn F Pierce
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

View more
  81 in total

1.  Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B).

Authors:  Thomas F Lerch; Michael S Chapman
Journal:  Virology       Date:  2011-12-09       Impact factor: 3.616

2.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

3.  Directing integrin-linked endocytosis of recombinant AAV enhances productive FAK-dependent transduction.

Authors:  Paul M Kaminsky; Nicholas W Keiser; Ziying Yan; Diana C M Lei-Butters; John F Engelhardt
Journal:  Mol Ther       Date:  2012-01-10       Impact factor: 11.454

4.  Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 Å resolution.

Authors:  Thomas F Lerch; Jason K O'Donnell; Nancy L Meyer; Qing Xie; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Structure       Date:  2012-06-21       Impact factor: 5.006

Review 5.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

6.  Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.

Authors:  R Sayroo; D Nolasco; Z Yin; Y Colon-Cortes; M Pandya; C Ling; G Aslanidi
Journal:  Gene Ther       Date:  2015-10-08       Impact factor: 5.250

Review 7.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

8.  Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors.

Authors:  Sanford L Boye; Antonette Bennett; Miranda L Scalabrino; K Tyler McCullough; Kim Van Vliet; Shreyasi Choudhury; Qing Ruan; James Peterson; Mavis Agbandje-McKenna; Shannon E Boye
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

Review 9.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

10.  Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking.

Authors:  Balasubramanian Venkatakrishnan; Joseph Yarbrough; John Domsic; Antonette Bennett; Brian Bothner; Olga G Kozyreva; R Jude Samulski; Nicholas Muzyczka; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.